基于生物信息学分析评估 hsa-mir-124 在预测乳腺浸润性癌临床结局中的作用。
Evaluation of the Role of hsa-mir-124 in Predicting Clinical Outcome in Breast Invasive Carcinoma Based on Bioinformatics Analysis.
机构信息
The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, Nanjing, China.
Department of Clinical Laboratory, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
出版信息
Biomed Res Int. 2020 Mar 3;2020:1839205. doi: 10.1155/2020/1839205. eCollection 2020.
PURPOSE
Breast invasive carcinoma (BRCA) is the most common malignant tumor. MiR-124 plays a tumor-suppressive role in human cancer. However, the clinical significance of miR-124 in BRCA remains unclear. The aim of this study was to evaluate the association of hsa-mir-124 expression and the clinicopathological characteristics in BRCA using database analysis.
METHODS
The clinical data and expression profiles of hsa-mir-124 were obtained from the cancer genome atlas for BRCA (TCGA_BRCA). Then, the prognostic value of hsa-mir-124 in BRCA was investigated using the Cox Regression test, and the association of hsa-mir-124 and pathology TNM stages and pathologic stages were measured by the Kruskal-Wallis test and Wilcox. test. In addition, the association of hsa-mir-124 and tumor molecular phenotypes was performed using the Chi-Square test.
RESULTS
We found that the overall survival of patients with high expression of hsa-mir-124-1 and hsa-mir-124-2 was better than that of patients with low expression of hsa-mir-124-1 and hsa-mir-124-2. And the expression of hsa-mir-124-1, hsa-mir-124-2, and hsa-mir-124-3 was mainly enriched in T1/T2 stages, NO/N1 stages, and M0 stages. Then, the expression of hsa-mir-124-1, hsa-mir-124-2, and hsa-mir-124-3 was negatively associated with tumor lymph node metastasis. Moreover, the expression of hsa-mir-124 was associated with tumor molecular phenotype in breast invasive carcinoma.
CONCLUSION
Our findings indicated that hsa-mir-124 expressions were associated with overall survival, TNM stages, pathologic characteristics, and tumor molecular phenotype in BRCA via TCGA_BRCA database, providing a new biomarker and a potential therapeutic target for BRCA patients.
目的
乳腺浸润性癌（BRCA）是最常见的恶性肿瘤。miR-124 在人类癌症中发挥着肿瘤抑制作用。然而，miR-124 在 BRCA 中的临床意义尚不清楚。本研究旨在通过数据库分析评估 hsa-mir-124 的表达与 BRCA 临床病理特征的相关性。
方法
从癌症基因组图谱（TCGA_BRCA）中获取 hsa-mir-124 的临床数据和表达谱。然后，使用 Cox 回归检验研究 hsa-mir-124 在 BRCA 中的预后价值，并通过 Kruskal-Wallis 检验和 Wilcox 检验测量 hsa-mir-124 与病理 TNM 分期和病理分期的关系。此外，使用卡方检验研究 hsa-mir-124 与肿瘤分子表型的关系。
结果
我们发现 hsa-mir-124-1 和 hsa-mir-124-2 高表达患者的总生存率优于 hsa-mir-124-1 和 hsa-mir-124-2 低表达患者。hsa-mir-124-1、hsa-mir-124-2 和 hsa-mir-124-3 的表达主要富集在 T1/T2 期、NO/N1 期和 M0 期。然后，hsa-mir-124-1、hsa-mir-124-2 和 hsa-mir-124-3 的表达与肿瘤淋巴结转移呈负相关。此外，hsa-mir-124 的表达与乳腺浸润性癌的肿瘤分子表型相关。
结论
通过 TCGA_BRCA 数据库，我们的研究结果表明，hsa-mir-124 的表达与 BRCA 的总生存率、TNM 分期、病理特征和肿瘤分子表型相关，为 BRCA 患者提供了新的生物标志物和潜在的治疗靶点。
Zotero 插件